Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using 1H HR-MAS spectroscopy and histopathology

Yang,Jehoon; Song,Kyoung   Doo; Kim,Jae-Hun; Im,Geun-Ho; Yoon,Seulgi; Namgung,Misun; Hwang,Jung-Hyun; Lee,Jung  Hee; Choi,Dongil

doi:10.3892/mmr.2013.1690

Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using 1H HR-MAS spectroscopy and histopathology

Authors:
- Jehoon Yang
- Kyoung Doo Song
- Jae-Hun Kim
- Geun-Ho Im
- Seulgi Yoon
- Misun Namgung
- Jung-Hyun Hwang
- Jung Hee Lee
- Dongil Choi
View Affiliations

Affiliations: Department of Medical Science, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea, Center for Molecular and Cellular Imaging, Samsung Biomedical Research Institute, Suwon, Republic of Korea, Laboratory Animal Research Center, Samsung Biomedical Research Institute, Suwon, Republic of Korea, Department of Chemistry, Hankook University of Foreign Studies, Seoul, Republic of Korea
Published online on: September 18, 2013 https://doi.org/10.3892/mmr.2013.1690
Pages: 1425-1431

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis inhibition is an attractive therapeutic strategy in the management of solid tumors. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are key factors in growth and neovascularization of hepatocellular carcinoma (HCC). Brivanib is a novel, orally available dual tyrosine kinase inhibitor that selectively targets the key angiogenesis receptors VEGF‑R2, FGF‑R1 and FGF‑R2. Recently, high‑resolution magic angle spinning magnetic resonance spectroscopy (HR‑MAS MRS) has provided the opportunity to investigate more detailed metabolic profiles from intact tissue specimens that are correlated with histopathology and is thus, a promising tool for monitoring changes induced by treatment. In the present study, 1H HR‑MAS MRS and immunohistochemistry were used to investigate the antitumor efficacy of brivanib in HCC xenograft models. Tumor growth was significantly suppressed in brivanib‑treated mice compared with the controls and treatment was associated with the inhibition of angiogenesis, increased apoptosis and inhibition of cell proliferation. Furthermore, HR‑MAS techniques showed altered metabolic profiles between the two groups. HR‑MAS spectra demonstrated a significant decrease in choline metabolite levels in the treated groups, concurrent with decreased cell proliferation and increased apoptosis. The results showed that 1H HR‑MAS MRS provides quantitative metabolite information that may be used to analyze the efficacy of brivanib treatment in Hep3B tumor xenografts. Thus, the HR‑MAS MRS technique may be a complementary method to support histopathological results and increase its potential for use in the clinic.

View Figures

View References

1	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
2	Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 9(Suppl 1): 2–10. 2004. View Article : Google Scholar
3	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
4	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
5	Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
6	Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
8	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
9	Diaz-Padilla I and Siu LL: Brivanib alaninate for cancer. Expert Opin Investig Drugs. 20:577–586. 2011. View Article : Google Scholar : PubMed/NCBI
10	Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S and Tran E: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res. 14:6146–6153. 2008. View Article : Google Scholar
11	Marathe PH, Kamath AV, Zhang Y, D’Arienzo C, Bhide R and Fargnoli J: Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol. 65:55–66. 2009. View Article : Google Scholar
12	Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE and Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 19:30–40. 2006. View Article : Google Scholar : PubMed/NCBI
13	Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC and Nicholson JK: High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc. 5:1019–1032. 2010. View Article : Google Scholar : PubMed/NCBI
14	Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS and Wu CL: Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 65:3030–3034. 2005.PubMed/NCBI
15	Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB and Kurhanewicz J: Quantitative analysis of prostate metabolites using ¹H HR-MAS spectroscopy. Magn Reson Med. 55:1257–1264. 2006. View Article : Google Scholar : PubMed/NCBI
16	Erb G, Elbayed K, Piotto M, Raya J, Neuville A, Mohr M, Maitrot D, Kehrli P and Namer IJ: Toward improved grading of malignancy in oligodendrogliomas using metabolomics. Magn Reson Med. 59:959–965. 2008. View Article : Google Scholar : PubMed/NCBI
17	Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, Carreira IM, Melo JB, Bernardo J, Gomes A, Sousa V, Carvalho L and Duarte IF: Metabolic profiling of human lung cancer tissue by ¹H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 9:319–332. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE and Gribbestad IS: Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA. 16:174–181. 2004. View Article : Google Scholar : PubMed/NCBI
19	Yang J, Kim JH, Im GH, Heo H, Yoon S, Lee J, Lee JH and Jeon P: Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI. Korean J Radiol. 12:602–610. 2011. View Article : Google Scholar : PubMed/NCBI
20	Frenette C and Gish R: Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol. 18:498–506. 2012. View Article : Google Scholar : PubMed/NCBI
21	Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi S: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 27:854–861. 1997. View Article : Google Scholar : PubMed/NCBI
22	Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H and Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 29:986–991. 1998. View Article : Google Scholar : PubMed/NCBI
23	Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY and Tarnawski AS: Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 16:552–557. 2003. View Article : Google Scholar : PubMed/NCBI
24	Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY and Yang YF: Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res. 17:2803–2809. 1997.PubMed/NCBI
25	Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J and Imamura M: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 23:455–464. 1996. View Article : Google Scholar : PubMed/NCBI
26	Adams J, Huang P and Patrick D: A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol. 6:486–492. 2002. View Article : Google Scholar : PubMed/NCBI
27	Laird AD and Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 12:51–64. 2003. View Article : Google Scholar : PubMed/NCBI
28	Li W, Liu ML, Cai JH, Tang YX, Zhai LY and Zhang J: Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo. Oncol Lett. 4:168–174. 2012.PubMed/NCBI
29	Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren S and Gribbestad IS: Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo ¹H MRS. NMR Biomed. 23:56–65. 2010. View Article : Google Scholar : PubMed/NCBI
30	Moestue S, Sitter B, Bathen TF, Tessem MB and Gribbestad IS: HR MAS MR spectroscopy in metabolic characterization of cancer. Curr Top Med Chem. 11:2–26. 2011. View Article : Google Scholar : PubMed/NCBI
31	Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS and Bathen TF: Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning ¹H magnetic resonance spectroscopy. Mol Cancer. 7:332008. View Article : Google Scholar